WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

Firm News

On August 10, 2017, Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

WilmerHale represented Apellis in this transaction, with a team led by Stuart Falber and included Mhairi Immermann and Alicia Lee.

Read Apellis' press release

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.